Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 3/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.42 |
| ▸ | F2RL3 | Q96RI0 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4800776 | 0.83 | PPARG (0.42) | PTGER1PTGDR2CYP1A2CYP3A4CYP2C8 | |
| SCHEMBL5365217 | 0.75 | PTGER1 (0.41) | PTGER1PTGDR2CYP1A2CYP3A4CYP2C8 | |
| SCHEMBL4806797 | 0.74 | PPARG (0.43) | F2RL3MAPK14 | |
| SCHEMBL5372921 | 0.74 | PTGDR2 (0.41) | PTGER1PTGDR2CYP1A2CYP3A4CYP2C8 | |
| SCHEMBL2946969 | 0.73 | PPARG (0.44) | — | |
| SCHEMBL4804980 | 0.72 | PPARG (0.43) | — | |
| SCHEMBL15998945 | 0.70 | NOTUM (0.57) | PTGER1PTGDR2CYP1A2CYP3A4CYP2C8 | |
| SCHEMBL2948464 | 0.69 | F2RL3 (0.41) | PTGER1PTGDR2CYP1A2CYP3A4CYP2C8 | |
| SCHEMBL2952988 | 0.67 | PPARG (0.45) | F2RL3MAPK14 | |
| SCHEMBL2945848 | 0.65 | ALDH1A1 (0.44) | PTGER1PTGDR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468375-B2 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-20050277662-A1 | Inhibitors of the HIV integrase enzyme | AGOURON PHARMACEUTICALS, INC | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277662-A1 | Inhibitors of the HIV integrase enzyme | IMPDH1, INTS9, TYMP | PTGER1 3835/4885PTGDR2 4540/4885CYP1A2 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.